GEN Exclusives

More »

GEN News Highlights

More »
Sep 1, 2011

CSL Negotiates Option to Pevion’s Candida Vaccine for Australia and New Zealand

  • Australian biotech firm CSL negotiated an option to license Pevion Biotech’s early clinical-stage therapeutic Candida vaccine for commercialization in Australia and New Zealand. The virosome-based vaccine is in development for the treatment of recurrent vulvovaginal candidiasis (chronic recurrent thrush). The firms in addition signed a long-term supply agreement under which CSL will manufacture specific biolgocial components used by Pevion in the in vitro assembly process for its virus-like particle virosome technology, which form the basis of the latter’s in-house and partnered pipeline products.

    Swiss firm Pevion’s virosome technology is a carrier and adjuvant system designed specifically for subunit vaccines, and has already been used for development of the marketed vaccines Epaxal® and Inflexal® V (both marketed by Crucell). The firm’s most advanced product, a virosome-based malaria vaccine candidate PEV3, has been outlicensed to Mymetics and is in late-stage clinical development. Mymetics also holds a license to a Phase I-stage HIV vaccine program.

    Pevion’s remaining in-house pipeline is headed by PEV7, which is being developed both for intramuscular delivery and intravaginal delivery for treating recurrent thrush. The firm reported postive data from an ongoing Phase I clinical trial back in November 2010. Pevion’s development programs in addition include a respiratory syncytial virus candidate, PEV4, which is in late-stage preclinical development, and an early clinical-stage HER2-targeting breast cancer candidate, PEV6, has been licensed out to BioLife Science. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?